Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 1997 (Second Quarter of Fiscal 1998)
Business Overview: The Company operates through two primary subsidiaries: Research & Diagnostic Systems, Inc. (R&D Systems) in the U.S., and R&D Systems Europe Ltd. R&D Systems focuses on biotechnology products (cytokines, antibodies, assay kits) and hematology controls/calibrators. In November 1997, the Company invested $1 million in ChemoCentryx, Inc. (CCX), a drug development company, and consolidated CCX into its financial statements.
Key Financial Metrics
| Metric | Quarter Ended 12/31/97 | Six Months Ended 12/31/97 |
|---|---|---|
| Net Sales | $15,472,857 | $31,010,000 |
| Gross Margin | $10,587,001 (68.4%) | $21,578,238 (69.6%) |
| Net Earnings | $3,127,984 | $6,390,366 |
| Diluted EPS | $0.16 | $0.33 |
| Cash & Short-Term Investments | $32,394,941 (Total) | N/A |
| Operating Cash Flow (6mo) | N/A | $8,926,641 |
| Debt | None (Unsecured line of credit: $750k, unused) | None |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% for the quarter and 9% for the six-month period compared to the prior year. R&D Systems sales grew 15% (quarter) and 16% (six months), while R&D Europe sales declined 7% due to the discontinuance of a molecular biology product line.
- Profitability: Net earnings increased 37% for the quarter and 44% for the six months. Gross margins improved to 68.4% (quarter) and 69.6% (six months) from 68.3% and 67.1% in the prior year, driven by higher sales of cytokines and antibodies.
- Expenses: Research and development expenses decreased 15% for both periods, primarily due to reduced payments under a joint research agreement in Europe and restructuring. Selling, general, and administrative expenses increased 5% (quarter) and 13% (six months) due to occupancy and advertising costs.
- Liquidity: Cash and short-term investments rose to $32.4 million from $24.8 million at the end of the prior fiscal year. Operating cash flow for the six months increased to $8.9 million from $6.0 million.
Guidance, Outlook, and Risks
- Outlook: Management expects to meet future capital requirements through available funds and operating cash flow. Planned capital additions for the remainder of fiscal 1998 are approximately $1.4 million.
- Strategic Investment: The Company is obligated to purchase an additional $4 million of preferred stock in ChemoCentryx, Inc. over the next two years upon achievement of milestones, potentially increasing ownership to 49%.
- Legal Proceedings: The Company is involved in patent infringement litigation with Streck Laboratories, Inc. regarding white blood cell hematology controls. The case is in early stages, with trial unlikely before 1999. The Company denies infringement and has filed counterclaims.
- Risks: Key risks include price competition in cytokine research products, acceptance of new products, and the success of research and development efforts.
- Stock Repurchase: The Company has extended its stock repurchase program and plans to retire up to an additional $5 million of common stock.
Investor Verification Checklist
- Verify the status and potential financial impact of the patent infringement lawsuit with Streck Laboratories, Inc.
- Monitor the milestones for the ChemoCentryx, Inc. investment to assess the timing and necessity of the additional $4 million capital commitment.
- Review the sustainability of the 15% reduction in R&D expenses and its impact on future product pipelines.
- Confirm the continued growth of the Biotechnology Division, which drove the majority of the earnings increase.
- Assess the effectiveness of the stock repurchase program in supporting share price and earnings per share.